Valor202020212022202320242025TTMFlujo de caja de las actividades de inversión-2.87 M-433 K-100 K-808 K-757 K-1.37 M-1.37 MFlujo de caja de las actividades financieras149.55 M274 K194.12 M6.77 M587 K276.18 M276.18 MFlujo de caja libre-168.37 M-109.16 M-56.42 M-80.33 M-106.81 M-121.72 M-121.71 M
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.